<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042740</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5380</org_study_id>
    <secondary_id>38553</secondary_id>
    <secondary_id>UM1AI068636</secondary_id>
    <nct_id>NCT04042740</nct_id>
  </id_info>
  <brief_title>Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection</brief_title>
  <acronym>PURGE-C</acronym>
  <official_title>Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of a fixed dose combination (FDC) of&#xD;
      glecaprevir/pibrentasvir (G/P) given for 4 weeks in acute hepatitis C (HCV)-infected&#xD;
      participants, with or without HIV-1 coinfection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two steps. In Step 1, participants will receive four weeks of&#xD;
      treatment with G/P for acute HCV infection and then followed 24 weeks post treatment.&#xD;
      Participants with HCV recurrence (reinfection, suspected relapse or undefined post-treatment&#xD;
      viremia) or HCV virologic failure before or at the Step 1 Week 16/SVR12 (sustained virologic&#xD;
      response 12 weeks post-treatment) visit may enter Step 2 for re-treatment. The remaining&#xD;
      participants complete the study at Week 28 of Step 1. The study primary and secondary outcome&#xD;
      measures pertain to Step 1.&#xD;
&#xD;
      In Step 2, participants will be re-treated with G/P with or without ribavirin (RBV) for up to&#xD;
      16 weeks, and followed for 24 weeks post treatment. Post-treatment follow-up for Step 2 will&#xD;
      include visits for SVR12 determination after re-treatment.&#xD;
&#xD;
      In Step 1, study visits are scheduled at study entry, weeks 1 and 2 (on-treatment), week 4&#xD;
      (treatment discontinuation), and weeks 8, 12, 16 and 28 (post-treatment follow-up). In Step&#xD;
      2, participants will have study visits during the re-treatment period, where the number of&#xD;
      visits depends on the re-treatment, and visits at 12 and 24 weeks post treatment. Study&#xD;
      visits may include physical examinations, clinical assessments, blood and urine collection,&#xD;
      questionnaires, and HCV re-infection prevention counseling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response at 12 weeks post-treatment (SVR12)</measure>
    <time_frame>Week 16 (12 weeks post treatment)</time_frame>
    <description>SVR12 defined as achieving unquantifiable HCV RNA (less than the lower limit of quantification [LLOQ] target detected [TD] or target not detected [TND]) at study visit 12 weeks post treatment. If a participant does not have any HCV RNA measurements in this time period then the participant will be considered as SVR12 failure, unless there are preceding and subsequent HCV RNA measurements that are both LLOQ (either TD or TND).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants who experienced adverse events (AEs)</measure>
    <time_frame>From study treatment initiation to 4 weeks after study treatment discontinuation (Week 8)</time_frame>
    <description>Study protocol required reporting of (1) AEs Grade greater than or equal to 2, (2) AEs that led to a change in study treatment regardless of grade and (3) AEs meeting ICH definition of SAE or Expedited AE (EAE) reporting requirement. DAIDS AE Grading Table (V2.1) and DAIDS EAE Manual (V2.0) are used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who complete 4 weeks of treatment without discontinuation due to AEs</measure>
    <time_frame>From study entry to Week 4</time_frame>
    <description>Number of participants who complete 4 weeks of treatment without discontinuation due to AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HCV RNA less than LLOQ</measure>
    <time_frame>Weeks 1, 2, 4, 8, 12, 28</time_frame>
    <description>Proportion of participants with HCV RNA less than LLOQ (TD or TND)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with HCV virologic failure</measure>
    <time_frame>Weeks 1, 2, 4</time_frame>
    <description>Virologic failure defined as failure to achieve unquantifiable HCV RNA and confirmed increase in HCV RNA greater than 1 log10 from on-treatment nadir</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatitis C Infection</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Glecaprevir/Pibrentasvir (G/P)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Step 1, participants will receive G/P FDC tablets to be taken orally once daily for 4 weeks.&#xD;
Any participant who experiences viral re-infection, suspected relapse, virologic failure, or undefined post-treatment HCV viremia may enter Step 2. In Step 2, participants may receive G/P FDC tablets orally once daily for 8-16 weeks. Some participants may also receive ribavirin (RBV) tablets orally twice daily. Alternate regimens are allowed in Step 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir (G/P)</intervention_name>
    <description>Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.</description>
    <arm_group_label>Glecaprevir/Pibrentasvir (G/P)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Tablets containing 200 mg of ribavirin. RBV dosed according to weight-based and renal dosing tables in study protocol.</description>
    <arm_group_label>Glecaprevir/Pibrentasvir (G/P)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Acute HCV infection (or reinfection) within 24 weeks prior to entry.&#xD;
&#xD;
          -  Detectable HCV RNA at the screening visit.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Any HCV treatment during the current acute HCV infection episode.&#xD;
&#xD;
          -  Known preexisting cirrhosis&#xD;
&#xD;
          -  Acute HIV-1 infection&#xD;
&#xD;
          -  Presence of active or acute AIDS-defining opportunistic infections, active serious&#xD;
             infection (other than HIV-1 or HCV), active hepatitis B virus (HBV) or active&#xD;
             hepatitis A virus (HAV)&#xD;
&#xD;
          -  Chronic use of systemically administered immunosuppressive agents&#xD;
&#xD;
          -  History of solid organ transplantation.&#xD;
&#xD;
          -  History of conditions that could interfere with the absorption of the study drug.&#xD;
&#xD;
          -  Concurrent use of prohibited medications&#xD;
&#xD;
          -  Known hypersensitivity to glecaprevir or pibrentasvir, the metabolites, or parts of&#xD;
             the formulation.&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Males with pregnant female partner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Y. Kim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital (MGH) CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanna Naggie, MD, MHS</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University Medical Center CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Wyles, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado Hospital CRS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ucsd, Avrc Crs (701)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrickx M. Steven, B.S.N</last_name>
      <phone>619-708-1210</phone>
      <email>smhendrickx@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Constance A. Benson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS (6101)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne G Fiorillo, MSPH</last_name>
      <phone>303-724-5931</phone>
      <email>suzanne.fiorillo@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas B Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Whitman-Walker Institute, Inc. CRS (31791)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avery Wimpelberg, CCRC</last_name>
      <phone>202-797-3589</phone>
      <email>awimpelberg@whitman-walker.org</email>
    </contact>
    <investigator>
      <last_name>Sarah Henn, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS (5802)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ericka Patrick</last_name>
      <phone>404-616-6313</phone>
      <email>erpatri@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Carlos del Rio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Becker, PA-C</last_name>
      <phone>410-614-4036</phone>
      <email>rbecke22@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly Dooley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ACTG CRS (101)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teri Flynn, RN, MSN, ANP</last_name>
      <phone>1-617-724-0072</phone>
      <email>tflynn@partners.org</email>
    </contact>
    <investigator>
      <last_name>Rajesh T. Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS (7804)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaun R. Barcavage, NP</last_name>
      <phone>212-746-7204</phone>
      <email>srb4001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Kristin Marks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Physicians and Surgeons CRS (30329)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Palmer, PA</last_name>
      <phone>212-305-3178</phone>
      <email>sp500@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Magdalena Sobieszczyk, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Upton CRS (7803)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fry, MSN, FNP</last_name>
      <phone>212-746-4166</phone>
      <email>ref2007@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Marshall J. Glesby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs (3201)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Straub, RN, BSN, MPH</last_name>
      <phone>919-843-9975</phone>
      <email>bstraub@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>David A. Wohl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greensboro CRS (3203)</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Epperson, RN, BSN, CCRC</last_name>
      <phone>336-832-7888</phone>
      <email>kim.epperson@mosecone.com</email>
    </contact>
    <investigator>
      <last_name>Cornelius Van Dam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Miriam Hosp. ACTG CRS (2951)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Poethke, RN</last_name>
      <phone>401-793-4971</phone>
      <email>ppoethke@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Karen T. Tashima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center CRS</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Rogers</last_name>
      <phone>972-807-7370</phone>
      <phone_ext>4420</phone_ext>
      <email>lrogers@aidsarms.org</email>
    </contact>
    <investigator>
      <last_name>Roger Bedimo, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS (1401)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Jonsson</last_name>
      <phone>206-744-8886</phone>
      <email>cjonsson@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Rachel Bender Ignacio, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (12101)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21045</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Hoagland</last_name>
      <phone>55 21 38659122</phone>
      <email>brenda.hoagland@ipec.fiocruz.br</email>
    </contact>
    <investigator>
      <last_name>Beatriz Grinsztejn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS (5401)</name>
      <address>
        <city>San Juan</city>
        <zip>00931</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Davila, BS, MS</last_name>
      <phone>(787) 767-9192</phone>
      <email>sylvia.davila@upr.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge Santana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Hepatitis C Infection</keyword>
  <keyword>Glecaprevir</keyword>
  <keyword>Pibrentasvir</keyword>
  <keyword>4 weeks</keyword>
  <keyword>Direct-acting antivirals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in the publication, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.</ipd_time_frame>
    <ipd_access_criteria>With whom?&#xD;
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.&#xD;
For what types of analyses?&#xD;
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.&#xD;
By what mechanism will data be made available?&#xD;
Researchers may submit a request for access to data using the AIDS Clinical Trials Group &quot;Data Request&quot; form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

